Tirzepatide
A newer dual-action medication that targets both GIP and GLP-1 receptors. In head-to-head trials, it produced more weight loss than semaglutide.
Tirzepatide is a "twincretin" — it activates both GLP-1 and GIP receptors, two gut hormones that control appetite, insulin, and metabolism. This dual action produced up to 22.5% weight loss in trials, outperforming semaglutide.
Good for you if: You have type 2 diabetes or obesity and your doctor recommends a GLP-1-class medication. Tirzepatide may be preferred if maximum weight loss is a priority.
Dive deeper into the researchCommon side effects
- GI side effects similar to semaglutide — nausea in 25–35% of users
- Muscle loss concern applies to all GLP-1 drugs — resistance training is essential
- Same serious risk profile: pancreatitis, gallbladder, thyroid (rare)
What does tirzepatide do?
Unlike semaglutide which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that helps regulate insulin, appetite, and fat metabolism. By targeting both pathways, tirzepatide produces stronger effects on weight and blood sugar.
In the SURMOUNT-1 trial, people on the highest dose (15 mg/week) lost an average of 22.5% of their body weight — the most of any approved medication. Blood sugar improvements were equally impressive.
Who is it for?
- Type 2 diabetes — approved as Mounjaro for blood sugar control
- Weight management — approved as Zepbound in the US; India availability is growing
- People who want maximum weight loss and have discussed the trade-offs with their doctor
Not for type 1 diabetes, and not recommended if you have a history of pancreatitis or medullary thyroid carcinoma.
How it's taken
Start at 2.5 mg/week for 4 weeks, then increase by 2.5 mg every 4 weeks. Target dose ranges from 5 mg to 15 mg/week depending on your goals and tolerance.
Inject once weekly in your stomach, thigh, or upper arm. Same day each week, any time of day.
Availability in India
Tirzepatide is available in India as Mounjaro (Eli Lilly) for type 2 diabetes. Availability is expanding but not yet as widespread as Ozempic. Cost is approximately ₹8,000–₹18,000 per month depending on dose. Prescription required from an endocrinologist.
Track your GLP-1 biomarkers with eterni
HbA1c, fasting insulin, body composition, and more — monitored over time so you can see if your protocol is working.
Get early accessFrequently Asked Questions
Is tirzepatide better than semaglutide?
In head-to-head trials, tirzepatide produced more weight loss (22.5% vs 15–17%) and comparable blood sugar improvements. However, individual responses vary. Your doctor can help determine which is right for you based on your health profile, available options, and cost.
What are the most common side effects?
GI side effects are most common — nausea (25–35%), diarrhoea, constipation, and reduced appetite. These typically improve over the first 4–8 weeks. Serious but rare risks include pancreatitis and gallbladder disease.
Is tirzepatide available in India?
Yes, as Mounjaro (Eli Lilly) for type 2 diabetes. Availability is expanding in major cities. Cost ranges from ₹8,000–₹18,000 per month. Weight-management branding (Zepbound) is not yet available in India.
Does tirzepatide cause muscle loss?
Yes, like all GLP-1 class drugs. Resistance training, adequate protein (1.2–1.6 g/kg/day), and creatine supplementation are essential to preserve lean mass while on tirzepatide.
How it works in your body
Tirzepatide is a single molecule that activates two receptors: GLP-1 (which reduces appetite and improves insulin) and GIP (which enhances insulin sensitivity and may improve fat metabolism). The GIP component may also help preserve muscle mass better than GLP-1-only drugs, though this needs more study.
Clinical trial data
- SURMOUNT-1: 22.5% weight loss at 15 mg vs 2.4% placebo over 72 weeks
- SURMOUNT-2: 14.7% weight loss in people with type 2 diabetes and obesity
- SURPASS-2: Superior HbA1c reduction vs semaglutide 1 mg (head-to-head)
- SURPASS-4: Cardiovascular safety confirmed in high-risk diabetes patients
Biomarker monitoring
Same panel as semaglutide: HbA1c, fasting insulin, HOMA-IR, lipid panel (ApoB, triglycerides), liver enzymes, kidney function, vitamin B12, and thyroid panel.
Side effects & safety
Tirzepatide's side-effect profile is similar to semaglutide, with slightly lower GI side-effect rates in some trials.
- Nausea — 25–35% (slightly lower than semaglutide in head-to-head data)
- Diarrhoea — 15–25%
- Constipation — 10–15%
- Muscle loss — same concern as all GLP-1 drugs; resistance training and protein are essential
- Injection site reactions — mild redness or itching in ~5% of users
- Pancreatitis — severe abdominal pain radiating to the back = emergency
- Gallbladder disease — increased risk with rapid weight loss
- Thyroid C-cell tumours — contraindicated with MTC/MEN 2 history
Know what's working. Know what's not.
eterni connects your lab results, medications, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist